{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T12:19:50Z","timestamp":1775823590951,"version":"3.50.1"},"reference-count":30,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"unspecified","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","award":["HX-H2209259"],"award-info":[{"award-number":["HX-H2209259"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,2,10]]},"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Nafamostat mesylate (NM) is widely recognised as a premier anticoagulant, especially in Japan and Korea. However, it has not yet been used as an anticoagulant in double plasma molecular adsorption system (DPMAS) plus sequential half-dose plasmapheresis (PE) therapy. This study aims to comprehensively evaluate the safety and efficacy of NM-integrated anticoagulation during DPMAS plus sequential half-dose PE therapy for patients with liver failure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>A two-arm, open-label, parallel, randomised controlled trial involving 132 patients with liver failure will be conducted in China. Eligible participants will be randomly allocated to either the nafamostat mesylate integrative anticoagulation group or the heparin integrative anticoagulation group, employing a central randomisation system at a 1:1 ratio throughout the course of DPMAS plus sequential half-dose PE therapy. The primary outcome includes the number of successfully completed DPMAS plus sequential half-dose PE therapy. The secondary outcomes include liver function indicators, extracorporeal circulation pressures, coagulation function parameters, all-cause mortality rates and survival rates. Clinical safety will be assessed by analysis of the number of bleeding events, the number of clotting events and adverse events. Outcome analyses will be performed on both the intention-to-treat population, which includes all patients randomised, and the per-protocol population, which includes eligible patients who adhere to the planned treatment and follow-ups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>The trial protocol was approved by the Biomedical Research Ethics Committee of West China Hospital of Sichuan University (approval number (2022)860). During the protocol revision process, all changes were reexamined and reapproved by the Biomedical Research Ethics Committee of West China Hospital of Sichuan University. The results will be presented at national and international conferences and published in peer-reviewed journals.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>ChiCTR2200064725.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-098898","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T11:08:00Z","timestamp":1740481680000},"page":"e098898","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Integrative anticoagulation of nafamostat mesylate in double plasma molecular adsorption system plus sequential half-dose plasmapheresis for patients with liver failure: a randomised controlled trial protocol"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7690-2786","authenticated-orcid":false,"given":"Xiankun","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Nephrology, Kidney Research Institute, West China Hospital of Sichuan University, Chengdu, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kidney Research Institute, West China Hospital of Sichuan University, Chengdu, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiwen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kidney Research Institute, West China Hospital of Sichuan University, Chengdu, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Liao","sequence":"additional","affiliation":[{"name":"Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingying","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kidney Research Institute, West China Hospital of Sichuan University, Chengdu, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lang","family":"Bai","sequence":"additional","affiliation":[{"name":"Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1155-4802","authenticated-orcid":false,"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kidney Research Institute, West China Hospital of Sichuan University, Chengdu, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"2025101811112035000_15.2.e098898.1","doi-asserted-by":"crossref","first-page":"16041","DOI":"10.1038\/nrdp.2016.41","article-title":"Acute-on-chronic liver failure in cirrhosis","volume":"2","author":"Arroyo","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2025101811112035000_15.2.e098898.2","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/CCM.0000000000005824","article-title":"Guidelines for the Management of Adult Acute and Acute-on-Chronic Liver Failure in the ICU: Neurology, Peri-Transplant Medicine, Infectious Disease, and Gastroenterology Considerations","volume":"51","author":"Nanchal","year":"2023","journal-title":"Crit Care Med"},{"key":"2025101811112035000_15.2.e098898.3","doi-asserted-by":"crossref","DOI":"10.2196\/45395","article-title":"Evaluating the Effect of Artificial Liver Support on Acute-on-Chronic Liver Failure Using the Quantitative Difference Algorithm: Retrospective Study","volume":"7","author":"Huang","year":"2023","journal-title":"JMIR Form Res"},{"key":"2025101811112035000_15.2.e098898.4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1499-3872(16)60084-X","article-title":"Plasma exchange-centered artificial liver support system in hepatitis B virus-related acute-on-chronic liver failure: a nationwide prospective multicenter study in China","volume":"15","author":"Chen","year":"2016","journal-title":"Hepatobiliary & Pancreatic Diseases International"},{"key":"2025101811112035000_15.2.e098898.5","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3139929","article-title":"The Clinical Efficacy of Double Plasma Molecular Absorption System Combined with Plasma Exchange in the Treatment of Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis","volume":"2022","author":"Bai","year":"2022","journal-title":"J Healthc Eng"},{"key":"2025101811112035000_15.2.e098898.6","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/jca.21690","article-title":"Therapeutic effect of double plasma molecular adsorption system and sequential half-dose plasma exchange in patients with HBV-related acute-on-chronic liver failure","volume":"34","author":"Yao","year":"2019","journal-title":"J Clin Apher"},{"key":"2025101811112035000_15.2.e098898.7","doi-asserted-by":"crossref","unstructured":"Guo X , Wu F , Guo W , et al . Comparison of plasma exchange, double plasma molecular adsorption system, and their combination in treating acute-on-chronic liver failure. J Int Med Res 2020;48. doi:10.1177\/0300060520932053","DOI":"10.1177\/0300060520932053"},{"key":"2025101811112035000_15.2.e098898.8","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/MPG.0000000000003759","article-title":"Combination of Plasma Exchange and Adsorption Versus Plasma Exchange in Pediatric Acute Liver Failure: A Multicenter Cohort Study","volume":"76","author":"Gao","year":"2023","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2025101811112035000_15.2.e098898.9","doi-asserted-by":"crossref","DOI":"10.1002\/jca.22140","article-title":"Comparative efficacy of double plasma molecular adsorption system combined with plasma exchange versus plasma exchange in treating acute-on-chronic liver failure due to hepatitis B: A meta-analysis","volume":"39","author":"Zhang","year":"2024","journal-title":"J Clin Apher"},{"key":"2025101811112035000_15.2.e098898.10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000500408","article-title":"Safety and Efficacy of Regional Citrate Anticoagulation during Plasma Adsorption Plus Plasma Exchange Therapy for Patients with Acute-on-Chronic Liver Failure: A Pilot Study","volume":"48","author":"Ma","year":"2019","journal-title":"Blood Purif"},{"key":"2025101811112035000_15.2.e098898.11","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1056\/NEJMc1109231","article-title":"Coagulopathy of chronic liver disease","volume":"365","author":"De Gottardi","year":"2011","journal-title":"N Engl J Med"},{"key":"2025101811112035000_15.2.e098898.12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000528062","article-title":"Bilirubin Removal by Plasmafiltration-Adsorption: Ex vivo Adsorption Kinetics Model and Single Case Report","volume":"52","author":"Marcello","year":"2023","journal-title":"Blood Purif"},{"key":"2025101811112035000_15.2.e098898.13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000489921","article-title":"Biocompatibility and Cytotoxic Evaluation of New Sorbent Cartridges for Blood Hemoperfusion","volume":"46","author":"Pomar\u00e8 Montin","year":"2018","journal-title":"Blood Purif"},{"key":"2025101811112035000_15.2.e098898.14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1744-9987.1998.tb00090.x","article-title":"Bilirubin adsorbent column for plasma perfusion","volume":"2","author":"Takenaka","year":"1998","journal-title":"Ther Apher"},{"key":"2025101811112035000_15.2.e098898.15","first-page":"129","article-title":"Expert consensus on application of nafamostat mesilate in anticoagulation for blood purification","volume":"47","year":"2024","journal-title":"Shanghai Medical Journal"},{"key":"2025101811112035000_15.2.e098898.16","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/aor.13097","article-title":"Sustained Deterioration of Hepatic Oxygenation After Nafamostat Mesilate-Induced Anaphylactic Shock During Hemodiafiltration","volume":"42","author":"Ookawara","year":"2018","journal-title":"Artif Organs"},{"key":"2025101811112035000_15.2.e098898.17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000485724","article-title":"Current Practices in Acute Blood Purification Therapy in Japan and Topics for Further Study","volume":"196","author":"Sadahiro","year":"2018","journal-title":"Contrib Nephrol"},{"key":"2025101811112035000_15.2.e098898.18","first-page":"506","article-title":"SPIRIT 2013 Statement: defining standard protocol items for clinical trials","volume":"38","author":"Chan","year":"2015","journal-title":"Rev Panam Salud Publica"},{"key":"2025101811112035000_15.2.e098898.19","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-019-09946-3"},{"key":"2025101811112035000_15.2.e098898.20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/4909742","article-title":"Good Tolerance of Citrate Accumulation due to Plasma Exchange among Patients with Acute-on-Chronic Liver Failure: A Prospective, Observational Study","volume":"2018","author":"Ma","year":"2018","journal-title":"Canadian Journal of Gastroenterology and Hepatology"},{"key":"2025101811112035000_15.2.e098898.21","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-005-0044-y"},{"key":"2025101811112035000_15.2.e098898.22","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrneph.2011.88","article-title":"What are the anticoagulation options for intermittent hemodialysis?","volume":"7","author":"Davenport","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"2025101811112035000_15.2.e098898.23","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2012.03.017"},{"key":"2025101811112035000_15.2.e098898.24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2215\/CJN.0000000000000351","article-title":"Regional Citrate Anticoagulation versus No Anticoagulation for CKRT in Patients with Liver Failure with Increased Bleeding Risk","volume":"19","author":"Bai","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025101811112035000_15.2.e098898.25","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jca.22019","article-title":"Regional citrate anticoagulation vs systemic heparin anticoagulation for double-filtration plasmapheresis","volume":"38","author":"Teh","year":"2023","journal-title":"J Clin Apher"},{"key":"2025101811112035000_15.2.e098898.26","doi-asserted-by":"publisher","DOI":"10.5301\/ijao.5000465"},{"key":"2025101811112035000_15.2.e098898.27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/0391398820987565","article-title":"Sequential versus mono double plasma molecular adsorption system in acute-on-chronic liver failures: A propensity-score matched study","volume":"45","author":"Zhang","year":"2022","journal-title":"Int J Artif Organs"},{"key":"2025101811112035000_15.2.e098898.28","first-page":"908","article-title":"Double Plasma Molecular Adsorption System with Sequential Low-dose Plasma Exchange in Patients with Hepatitis B Virus-related Acute-on-chronic Liver Failure: A Prospective Study","volume":"11","author":"Wang","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"2025101811112035000_15.2.e098898.29","first-page":"433","article-title":"Efficacy and Economic Evaluation of Nonbiological Artificial Liver Therapy in Acute-on-chronic Hepatitis B Liver Failure","volume":"11","author":"Wu","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"2025101811112035000_15.2.e098898.30","doi-asserted-by":"crossref","DOI":"10.1186\/s13613-020-00795-0","article-title":"Uncertainty in the impact of liver support systems in acute-on-chronic liver failure: a systematic review and network meta-analysis","volume":"11","author":"Ocskay","year":"2021","journal-title":"Ann Intensive Care"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-098898","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:11:33Z","timestamp":1760811093000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-098898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,25]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1136\/bmjopen-2025-098898"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-098898","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}